Member Info for uxm484

Strong upside note market cap is currently less than 30 million.

1. Revenue Outlook (from company guidance)

FY26: $8.4m

FY27: $19.0m

FY28: $42.0m

(boosted by the Tempus collaboration)

This implies a CAGR of ~125% from FY26–28, i.e., very rapid growth.

2. Typical Valuation Multiples in Diagnostics

For early-stage diagnostics/precision medicine firms:

EV / Sales multiples range widely:

Struggling/small-cap: 2–4x sales

Growing, strategic partnerships, FDA approval: 5–10x sales

Premium leaders (e.g., Guardant, Natera in earlier phases): 10–15x sales

Given Renalytix has:

FDA approval ✔

Medicare reimbursement ✔

Strong partner (Tempus AI) ✔

…it could reasonably attract 5–10x sales if execution is strong.

3. Valuation Scenarios

Let’s apply multiples to FY28 revenue ($42m):

Bear case (3x sales): ~$126m EV

Base case (7x sales): ~$294m EV

Bull case (10x sales): ~$420m EV

Market cap ≈ EV (assuming minimal debt/cash netting effect).

4. Current Context

Current market cap (as of Sept 2025): ~$40–50m (depending on trading price).

That means: if Renalytix hits FY28 guidance and market assigns even a mid-range multiple, the stock could be worth 5–8x higher than today.

AI is saying it is more likely than not so even a moderate payout could be 50/100 times market cap.

Obviously risk involved but upside is huge and life changing.

Yes, but with some important nuances. Under ICSID arbitration rules, which govern Ascent’s claim, the situation is quite strict:

1. Binding Nature of ICSID Awards

An ICSID tribunal award is legally binding on the state.

By signing the ICSID Convention, Slovenia has agreed to recognize and enforce awards without domestic appeal.

So in principle, Slovenia cannot simply refuse to pay the award once issued.

2. Enforcement Mechanisms

If a state refuses payment voluntarily, the investor (Ascent) can seek enforcement in other jurisdictions:

ICSID awards can be enforced in any of the 170+ ICSID member countries.

This often involves seizing state assets abroad (like bank accounts, property, or subsidiaries).

Direct enforcement in the home country of the state (Slovenia) can be trickier, but international law gives strong tools for cross-border enforcement.

3. Practical Considerations

Political/financial risk: A government could delay or stall payment, creating collection headaches.

Impact on reputation: Refusing an ICSID award could harm Slovenia’s ability to attract foreign investment in the future.

✅ Bottom line

Legally, Slovenia is obligated to pay, and ICSID provides mechanisms for enforcement.

Realistically, payment delays are possible, but outright refusal is rare because it would violate international law and damage Slovenia’s credibility.

Step 1: Convert payout to GBP/USD

€350–450 million ≈ £310–400 million (roughly, assuming €1 ≈ £0.89)

Current market cap: ~£4 million → the market is heavily discounting the potential payout.

Step 2: Adjust for corporate structure and risk

Let’s assume the payout goes to shareholders after legal costs (~10–15%):

Net payout ≈ £265–360 million

Number of shares outstanding: ~1.3 billion (from recent filings)

Net payout per share ≈ £0.20–0.28/share

Current share price: ~£0.003/share → huge potential upside if award is realized.

Step 3: Estimate post-award market cap

If the market fully prices in a moderate award (~£310–400M), the market cap could realistically jump from £4M → £300–400M.

That’s 75–100× the current market cap, reflecting how tiny the current valuation is relative to the claim.

Step 4: Realistic risk-adjusted view

Market may apply a 50–70% probability discount due to tribunal uncertainty, regulatory challenges, or payment delays:

Risk-adjusted market cap ≈ £150–250M

Still 30–60× higher than today, showing the enormous potential leverage if the award goes in their favor.

Bottom line:

The current market cap is almost entirely ignoring the ECT claim. If Ascent wins a moderate payout, the stock could theoretically explode in value—but timing, legal certainty, and investor confidence will strongly influence how much of that potential is priced in.

Claimed amount: €656.5 million.

Nature of claim: Regulatory ban on fracking → alleged indirect expropriation.

Tribunal type: ICSID under the ECT and UK–Slovenia BIT.

Historical precedent: ECT expropriation cases typically award 30–80% of the claimed amount, depending on:

How directly the regulatory action affected the investment.

Whether the state can justify the action as legitimate public interest.

Quality of the company’s damage calculation.

Step 2: Applying a Precedent-Based Range

Conservative outcome: Tribunal recognizes some loss but sees Slovenia’s ban as mostly justified → €150–250 million.

Moderate outcome: Tribunal agrees the ban caused significant harm but may adjust some calculations → €300–450 million.

Optimistic outcome: Tribunal fully supports Ascent’s valuation → €500–650 million (close to the full claim).

Step 3: Likely scenario

Given that environmental regulation is generally considered a legitimate public interest but this ban seems to have directly blocked Ascent’s operations, a moderate outcome (~€350–450 million) seems the most plausible.

This would still be a substantial payout relative to the company’s market capitalization and could materially impact the balance sheet.

There’s still a 20–30% chance of a very conservative or even zero award if the tribunal heavily favors Slovenia’s regulatory rationale.

That is revenue not market cap. Market cap would be far higher with those revenues. Don't forget profit margin are huge.

Either way it is up from these prices.

If only he told us at 6p it would be at 9.5p.

Should be a nice rise just like NYCT kept rising back in the days.

Fundamentals are strong, cash in the bank, lots of contracts incoming. It could just get stronger, stronger and stronger.

5.2 million. Loaded with cash now.

Not many especially if the 2 large sellers are buying again in the placing.

With cash in the bank and no further placing for a good time yet then it should attract the larger investment.

It could fly to 15p in a week now the uncertainity is removed.

Tiny discount. Small amount relative to the market cap. Cash in the bank.

The rise will be stronger with cash in the bank.

Or it will explode to 20/30p.

Momentum is strong. Expecting 15p tomorrow and then 20p by the end of the week.

Look at the tweet from Tempus. They are taking this business very seriously.

GL all.

18p prediction by Friday.

I know a friend looking to buy a large amount.

18p -Short term target. Lets goooo.

Chat gtp says

Yes — the RNS is very valuable relative to the size of the company. It has potential to move the share price (upwards) because the announced results materially de-risk part of the helium project, improve the project outlook, and give clearer pathway toward commercialisation.

The collaboration and entry into the US market are what truly make the difference. At 12p, it should already be trading above 20p.

Path to “multibagging” from ~£25M

For Renalytix, the numbers are asymmetric:

Revenue goal of £20–30M:

Needs ~30–40k tests (at ~£700/test). That is a tiny fraction of the chronic kidney disease (CKD) population in the U.S./UK (millions of patients).

→ If they reach this, the market cap could reasonably rerate to £100–200M+ (4–8× from here).

Scaling beyond (say £70M+ revenue):

That’s still under 0.5% penetration of the at-risk CKD population. With growing adoption, a £500M–£1B valuation is not crazy.

→ That would be 20–40× current levels if execution is solid.

So to get 100/200 million market cap estimate therefore 20/30 million revenue per year: Seems very easy

to hit revenue of 20/30 million how many tests needs to be sold

ChatGPT said:

Good question — let’s work it out step by step, carefully, in GBP terms since you asked about UK market cap.

1. What does Renalytix charge per KidneyIntelX test?

In the U.S., the CMS (Medicare) reimbursement rate has been set at $950 per test.

UK NHS pricing is less clear, but let’s use the $950 (~£730 at £1 = $1.30) as a baseline.

(If UK/EU pricing is lower, e.g. £400–£500 per test, we can also calculate that scenario.)

2. Target revenue

You asked about £20M–£30M revenue (≈ US$26M–US$39M at 1.3 FX).

3. Tests required at $950/test (~£730/test)

£20M revenue ÷ £730/test ≈ 27,400 tests

£30M revenue ÷ £730/test ≈ 41,100 tests

So roughly 27k–41k tests would be needed at the CMS rate.

4. If pricing were lower (say £500/test)

£20M ÷ £500 = 40,000 tests

£30M ÷ £500 = 60,000 tests

✅ Answer:

Renalytix would need to sell on the order of 27,000–41,000 KidneyIntelX tests (at ~£730/test) to hit £20–30M revenue, or 40,000–60,000 tests if pricing is closer to £500/test.

From chatgtp

From recent data:

Market cap ≈ £24-£25 million.

ADVFN UK

+4

Companies Market Cap

+4

Yahoo Finance

+4

Shares outstanding ~ 330 million.

ADVFN UK

+1

Revenue is currently very low (TTM revenue ~$2-3 million) and losses are significant.

Companies Market Cap

+2

StockAnalysis

+2

So the valuation is currently very modest.

What could it be, in the UK, under different scenarios

Here are some scenario-based projections, translating them into GBP, based on multiples typical in diagnostics / health-tech companies. Assumes exchange rate ~ £1 = US$1.25–1.35 (just as a rough guide; real rate will vary). I’ll approximate £1 ≈ US$1.30 for simplicity.

Scenario Assumptions (UK-relevant) Implied Revenue / Key Metrics Multiple / Valuation Metric Projected UK Market Cap

Modest growth Revenue increases to US$20–30M (~£15-£23M) in 2-3 years; still loss-making or small EBITDA loss; steady progress in reimbursement in UK/Europe; some pharma collaboration income. Assume revenue ~ £20M Valued at ~ 4-6× revenue, or maybe ~10× when growth appears strong. £80M-£120M under 5×, up to ~£200M-£250M under 10× if confidence is high.

Strong scaling Revenue reaches ~US$80-100M (~£60-£75M), margins improving, losses reducing; UK/Europe regulatory + reimbursement largely in place; strong partnerships; credible path to profit. Revenue ~ £70M Revenue multiple ~ 7-10×, or if profit approaching, earnings multiples of ~15-20× (for biotech/diagnostics with growth). £500M-£800M plausible in this scenario.

Breakout / market leading Renalytix becomes a dominant player in kidney diagnostics, UK & EU scaled, recurring revenues, possibly new products; margin leverage; possible profitability; investor confidence strong. Revenue maybe ~ £150-200M+ Multiples perhaps 10-15× revenue, or higher on earnings if profitable. £1.5B-£3B+ conceivable in a very optimistic case.

What would need to happen to reach higher UK market caps

To move from ~£25M to, say, £200M or higher, here are the levers / risk points:

Revenue growth: UK & EU markets are large but regulatory / reimbursement requirements are more stringent; building sales networks, partnerships needed.

Reimbursement & regulatory approvals in UK/EU: Having payors accept the diagnostic tool(es); securing CE / IVDR approvals; guidelines that recommend its use.

Margin improvement: Diagnostics often have high fixed costs; scaling and automation, reducing Cost of Goods / Cost per test, better leverage will help.

Partnerships / Pharma collaborations: These can provide upfront / milestone payments, expand validation, build credibility.

Investor sentiment: Health tech / diagnostics multiples in UK decline or expand depending on macro / investor risk appetite; recent biotech trends matter.

Powerful momentum. More news hopefully soon.

Lets go......